Innovative Clinical Trials: The LUNG-MAP Study (Q38353591)

2 September 2017

1 reference

title

Innovative Clinical Trials: The LUNG-MAP Study (English)

1 reference

2 September 2017

R S Herbst

1 reference

2 September 2017

C E Steuer

1 reference

2 September 2017

V Papadimitrakopoulou

1 reference

2 September 2017

M W Redman

1 reference

2 September 2017

F R Hirsch

1 reference

2 September 2017

P C Mack

1 reference

2 September 2017

S S Ramalingam

1 reference

2 September 2017

D R Gandara

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

Clinical Pharmacology & Therapeutics

2 September 2017

published in

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

488-491

1 reference

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

2 September 2017

cites work

1 reference

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

7 January 2021

Cancer statistics, 2013

1 reference

7 January 2021

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

7 January 2021

New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response

1 reference

7 January 2021

The BATTLE trial: personalizing therapy for lung cancer

1 reference

7 January 2021

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

1 reference

7 January 2021

Oncogenic mutations of PIK3CA in human cancers

1 reference

7 January 2021

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression

1 reference

7 January 2021

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro

1 reference

7 January 2021

Cyclin-dependent kinase pathways as targets for cancer treatment

1 reference

7 January 2021

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

1 reference

7 January 2021

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

1 reference

7 January 2021

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

1 reference

7 January 2021

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

1 reference

7 January 2021

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

1 reference

7 January 2021

Signaling networks assembled by oncogenic EGFR and c-Met

1 reference

7 January 2021

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPT.88

1 reference

2 September 2017

1 reference